PARP-1 inhibitors (Astellas)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NamePARP-1 inhibitors (Astellas)
Drug Alias NamePARP-1 inhibitors (Fujisawa)FR-247304FR-257516FR-197262FR-255595 +[6] 
ClassificationSmall molecules
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitors
TargetsPoly (ADP-Ribose) polymerase
Therapy Area/IndicationsBrain IschemiaParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFujisawa Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstellas Pharma IncFujisawa Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsBrain IschemiaParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A